Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update
Galectin Therapeutics reported Q1 2026 results with a net loss of $5.1 million, significantly improved from $9.6 million in the prior year, driven by a drop in R&D spend to $2.2 million from $6.5 million. The company holds $14.1 million in cash plus $10 million in available credit, providing a runway through May 2027 without immediate need for dilutive financing. Positive biomarker data from the pivotal NAVIGATE trial showed statistically significant reductions in liver stiffness, supporting belapectin’s potential to impact disease progression in MASH cirrhosis patients.
Key figures
- Revenue
- 0
- Drug Name
- belapectin
- Guidance
- Cash runway extended to May 2027
- Phase Of Trial
- Phase 2b/3
- Net loss
- 5067000
- Rd expense
- 2231000
- G a expense
- 1846000
- Net loss prior year
- 9605000
- Cash and equivalents
- 14111000
- Total operating loss
- 4077000
- Credit line available
- 10000000
- Rd expense prior year
- 6485000
- G a expense prior year
- 1412000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.